Report Code: A03804 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Generic drugs are pharmaceutical drugs with similar chemical makeup of a branded drug. Generic drugs are cheaper in Japan and equivalent to branded drugs in dosage, strength, route of administration, quality, performance, and application. Generic drugs are subjected to government regulations of Japan; the Japanese Government has observed the growth of the generic drug market as imperative to Japans long-term economic health.
The major factors that contribute to the growth of the Japan generic drugs market include increasing prevalence of chronic diseases, diabetes & cardiovascular diseases, rising costs of branded medicines, growth in geriatric population, increasing healthcare expenditure, and high demand for generic medicines. However, issues such as the consistency and stability of generic drugs in Japan and lower reimbursement fees are expected to restrain the market development. Development of reliable & stable new product launch, support from the government, and adoption of mergers & acquisition strategies to launch new products by key vendors contribute to significant demand for generic drugs in the near future.
The Japan generic drugs market is segmented on the basis of product type, application, and distribution channel. On the basis of product type, the market is segmented into generic prescription medicines, super generics, and biosimilars. Based on application the market is divided into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. On the basis of distribution channel, the market is segmented into hospitals, pharmacies, private clinics, drug stores, retail pharmacies, and others.
The key players that operate in this market include Teva Pharmaceutical Industries Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Sawai Pharmaceuticals Co., Ltd., NIPRO Medical Corporation, Meiji Seika Pharma Co., Ltd., Towa Pharmaceutical Co., Ltd., Hikari Pharmaceutical Co., Ltd., Fuji Pharma Co., Ltd., Mylan N.V., and GlaxoSmithKline Plc.
Key Benefits
Japan Generic Drugs Market Report Highlights
Aspects | Details |
---|---|
By Product Type |
|
By Application |
|
By Distribution Channel |
|
By Region |
|
Key Market Players | Mylan N.V., Nichi-Iko Pharmaceutical Co., Ltd., Fuji Pharma Co., Ltd., NIPRO Medical Corporation, Towa Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Sawai Pharmaceuticals Co., Ltd., Hikari Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc. |
Loading Table Of Content...
Start reading.
This Report and over 71,229+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers